Back to top
more

Supernus Pharmaceuticals (SUPN)

(Delayed Data from NSDQ)

$30.07 USD

30.07
330,640

+0.76 (2.59%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $30.25 +0.18 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SUPN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Supernus Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 255 461 340 423 347
Receivables 144 166 149 141 87
Notes Receivable 0 0 0 0 0
Inventories 77 92 86 48 27
Other Current Assets 17 16 27 19 12
Total Current Assets 493 734 602 630 473
Net Property & Equipment 14 15 17 38 17
Investments & Advances 17 94 119 350 592
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 32
Intangibles 717 819 902 442 25
Deposits & Other Assets 38 40 49 43 1
Total Assets 1,278 1,703 1,689 1,504 1,160
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 402 0 0 0
Accounts Payable 80 96 118 79 10
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 154 152 133 126 147
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 56 38 65 40 3
Total Current Liabilities 290 688 315 245 161
Mortgages 0 0 0 0 0
Deferred Taxes/Income 25 50 85 35 0
Convertible Debt 0 0 379 362 345
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 43 52 89 29
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 356 816 873 759 565
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 439 408 434 409 388
Retained Earnings 483 481 380 327 200
Other Equity -1 -3 2 9 7
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 922 886 816 745 595
Total Liabilities & Shareholder's Equity 1,278 1,703 1,689 1,504 1,160
Total Common Equity 922 886 816 745 595
Shares Outstanding 54.60 54.00 52.80 52.60 52.40
Book Value Per Share 16.88 16.41 15.45 14.16 11.36

Fiscal Year End for Supernus Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 255 200 152 632
Receivables NA 144 142 137 144
Notes Receivable NA 0 0 0 0
Inventories NA 77 83 91 91
Other Current Assets NA 17 24 45 16
Total Current Assets NA 493 449 424 883
Net Property & Equipment NA 14 14 14 15
Investments & Advances NA 17 25 37 54
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 717 758 779 800
Deposits & Other Assets NA 38 39 38 40
Total Assets NA 1,278 1,285 1,293 1,792
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 403
Accounts Payable NA 80 78 83 95
Current Portion Long-Term Debt NA 0 0 0 78
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 154 162 149 148
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 56 47 21 7
Total Current Liabilities NA 290 288 253 732
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 25 35 44 50
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 16 42 62
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 356 373 373 880
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 439 432 424 416
Retained Earnings NA 483 481 497 498
Other Equity NA -1 -1 -2 -2
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 922 912 920 912
Total Liabilities & Shareholder's Equity NA 1,278 1,285 1,293 1,792
Total Common Equity 0 922 912 920 912
Shares Outstanding 54.70 54.60 54.50 54.40 54.40
Book Value Per Share 0.00 16.88 16.74 16.91 16.77